Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 3, 2001, Pages 900-908

  Conway, James G ^a   Andrews, Robert C ^a   Beaudet, Beth ^a   Bickett, D Mark ^a   Boncek, Virginia ^a   Brodie, Thomas A ^a   Clark, Richard L ^b   Crumrine, R Christian ^a   Leenitzer, Michael A ^a   Mcdougald, Darryl L ^a   Han, Bajin ^a   Hedeen, Kevin ^a   Lin, Peiyuan ^a   Milla, Marcos ^a,c   Moss, Marcia ^a,d   Pink, Heather ^a   Rabinowitz, Michael H ^a   Tippin, Timothy ^a   Scates, Phillip W ^a   Selph, Jeffrey ^a   Stimpson, Stephen A ^a   Warner, Janet ^a   Becherer, J David ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GW 3333; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PEPTIDOGLYCAN POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE EDEMA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; JOINT DESTRUCTION; MALE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADAM PROTEINS; AMINOPYRIDINES; ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOOD PROTEINS; CARTILAGE; CATTLE; CHRONIC DISEASE; DIPEPTIDES; FREUND'S ADJUVANT; LIPOPOLYSACCHARIDES; MALE; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; PROTEIN BINDING; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034883069     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Collagenolytic cleavage products of collagen type I as chemoattractants for human dermal fibroblasts
2. TNF, immunity and inflammatory disease: Lessons of the past decade
3. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)
4. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
5. Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell walls
6. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120 kD fibroblastic cell-binding domain
7. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor
8. A metalloproteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes
9. Co-operation between interleukin-1 and the fibrinolytic system in the degradation of collagen by articular chondrocytes
10. Generation and biological characterization of membrane-bound uncleavable murine tumor necrosis factor
11. The effect of metalloproteinase inhibitor (GI5402) on tumor necrosis factor-α (TNF-α) and TNF-α receptors during human endotoxemia
12. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing
13. Modified assay for the determination of hydroxyproline in a tissue hydrolyzate
14. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis
15. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone
16. Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor
17. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice
18. Processing of tumour necrosis factor-α precursor by metalloproteinases
19. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts
20. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis
21. Metalloproteinase-mediated release of human Fas ligand
22. Diptheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF): Studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells
23. Chemotactic activity of collagen-like polypeptides for human peripheral blood monocytes
24. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
25. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
26. Regulation of tumour necrosis factor-α by a metalloproteinase inhibitor
27. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
28. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
29. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α
30. TNF(alpha) converting enzyme
31. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor
32. Role of metalloproteinases in the release of the IL-1 type II decoy receptor
33. Tumor necrosis factor-α mediates endotoxin-induced lung injury in platelet activating factor-primed rats
34. Superantigen can reactivate bacterial cell-wall-induced arthritis
35. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors
36. The fate of proTNF-α following inhibition of metalloprotease-dependent processing to soluble TNF-α in human monocytes
37. Tumor necrosis factor, other cytokines and disease
38. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo
39. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
40. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both the P55 and P75 receptor shedding and TNF-α processing in RA synovial membrane cultures
41. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes